Senate file 1494 would add metachromatic leukodystrophy to Minnesota newborn screening panel

Senate file 1494, introduced by Senator Miller, would add metachromatic leukodystrophy (MLD) to Minnesota's newborn screening panel to identify affected infants before symptoms appear.

Why it matters: Physicians and family advocates told the Senate Health and Human Services Finance and Policy Committee that early detection is essential because available curative and disease‑modifying treatments are far more effective when given before a child shows neurologic decline. Dr. Julie Isengard, an associate professor and pediatric neuropsychologist at the University of Minnesota, said untreated children "continually score lower and lower on repeated assessments" and that "there is no time to wait for an MLD diagnosis that comes only because a child has lost skills." Jennifer Braun, a nurse practitioner and clinical director at the Masonic Cancer Center, described a recent case in Minnesota in which a younger sibling benefited from treatment only after an older sibling was diagnosed.

Testimony and technical feasibility: Professor Michael Gelb (University of Washington) and family advocate Shanna Quimby described a mass spectrometry–based two‑step laboratory approach (sulfatide lipid analysis followed by ARSA enzyme testing). Gelb's lab pilot‑tested the method on 30,000 dried blood spots and reported identifying one true case with zero false positives in that pilot, and the speakers said laboratories would need to add a liquid chromatography module to existing mass spectrometers—an upgrade some state labs already have. Testimony included a claim about an FDA‑approved screening method timing that the record did not specify precisely; the committee requested additional technical and fiscal information from the Minnesota Department of Health before action.

Process and next steps: Senator Miller said the Minnesota Newborn Screening Advisory Committee considered MLD in October and voted unfavorably at that meeting, but the advisory committee will meet again April 15 with new information the sponsor said was not previously available. Miller said his preference is to proceed through that advisory process; he also asked the committee to consider including the change in the omnibus bill if the advisory committee does not approve it. The chair laid Senate file 1494 over for possible inclusion and requested a fiscal note and further information from the Department of Health.

What the committee record shows: The committee heard clinical descriptions of MLD (progressive motor and cognitive decline in infantile forms; cited incidence about 1 in 40,000 from testimony), family testimony about a child who died from MLD, and technical testimony about an assay that proponents say can be integrated into current newborn screening workflows. Committee members expressed sympathy for affected families and asked about the Department of Health's process and costs. No final vote was taken on the bill.